130 related articles for article (PubMed ID: 38607967)
1. NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.
Anastasaki C; Chatterjee J; Koleske JP; Gao Y; Bozeman SL; Kernan CM; Marco Y Marquez LI; Chen JK; Kelly CE; Blair CJ; Dietzen DJ; Kesterson RA; Gutmann DH
Neuro Oncol; 2024 Apr; ():. PubMed ID: 38607967
[TBL] [Abstract][Full Text] [Related]
2. NF1 mutation drives neuronal activity-dependent initiation of optic glioma.
Pan Y; Hysinger JD; Barron T; Schindler NF; Cobb O; Guo X; Yalçın B; Anastasaki C; Mulinyawe SB; Ponnuswami A; Scheaffer S; Ma Y; Chang KC; Xia X; Toonen JA; Lennon JJ; Gibson EM; Huguenard JR; Liau LM; Goldberg JL; Monje M; Gutmann DH
Nature; 2021 Jun; 594(7862):277-282. PubMed ID: 34040258
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
4. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects.
Tang Y; Gutmann DH
Cancer Manag Res; 2023; 15():667-681. PubMed ID: 37465080
[TBL] [Abstract][Full Text] [Related]
6. Midkine activation of CD8
Guo X; Pan Y; Xiong M; Sanapala S; Anastasaki C; Cobb O; Dahiya S; Gutmann DH
Nat Commun; 2020 May; 11(1):2177. PubMed ID: 32358581
[TBL] [Abstract][Full Text] [Related]
7. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology.
Toonen JA; Solga AC; Ma Y; Gutmann DH
J Exp Med; 2017 Jan; 214(1):17-25. PubMed ID: 27923908
[TBL] [Abstract][Full Text] [Related]
8. Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation.
de Andrade Costa A; Chatterjee J; Cobb O; Cordell E; Chao A; Schaeffer S; Goldstein A; Dahiya S; Gutmann DH
Neurooncol Adv; 2022; 4(1):vdab194. PubMed ID: 35187488
[TBL] [Abstract][Full Text] [Related]
9. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C
Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690
[TBL] [Abstract][Full Text] [Related]
10. Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors.
Jecrois ES; Zheng W; Bornhorst M; Li Y; Treisman DM; Muguyo D; Huynh S; Andrew SF; Wang Y; Jiang J; Pierce BR; Mao H; Krause MK; Friend A; Nadal-Nicolas F; Stasheff SF; Li W; Zong H; Packer RJ; Zhu Y
Dev Cell; 2021 Oct; 56(20):2871-2885.e6. PubMed ID: 34428430
[TBL] [Abstract][Full Text] [Related]
11. Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.
Anastasaki C; Mo J; Chen JK; Chatterjee J; Pan Y; Scheaffer SM; Cobb O; Monje M; Le LQ; Gutmann DH
Nat Commun; 2022 May; 13(1):2785. PubMed ID: 35589737
[TBL] [Abstract][Full Text] [Related]
12. Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.
Sharafi P; Varan A; Ersoy-Evans S; Ayter S
Childs Nerv Syst; 2024 Feb; 40(2):511-515. PubMed ID: 37401974
[TBL] [Abstract][Full Text] [Related]
13. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
14. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
Falzon K; Drimtzias E; Picton S; Simmons I
Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
[TBL] [Abstract][Full Text] [Related]
15. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
16. Identification of Mutation Regions on
Xu M; Xiong H; Han Y; Li C; Mai S; Huang Z; Ai X; Guo Z; Zeng F; Guo Q
Front Genet; 2018; 9():270. PubMed ID: 30087692
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.
Dasgupta B; Yi Y; Hegedus B; Weber JD; Gutmann DH
Cancer Res; 2005 Nov; 65(21):9843-50. PubMed ID: 16267007
[TBL] [Abstract][Full Text] [Related]
18. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
19. Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations.
Cassina M; Frizziero L; Opocher E; Parrozzani R; Sorrentino U; Viscardi E; Miglionico G; Midena E; Clementi M; Trevisson E
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31739524
[TBL] [Abstract][Full Text] [Related]
20. Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma.
Bolcekova A; Nemethova M; Zatkova A; Hlinkova K; Pozgayova S; Hlavata A; Kadasi L; Durovcikova D; Gerinec A; Husakova K; Pavlovicova Z; Holobrada M; Kovacs L; Ilencikova D
Neoplasma; 2013; 60(6):655-65. PubMed ID: 23906300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
